Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 2:55 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 59 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Premature Menopause Clear all

Conditions: Menopause, Premature
Interventions: Not listed
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 1
States / cities: Stanford, California

Conditions: Primary Ovarian Insufficiency, Unexplained Infertility
Interventions: Dehydroepiandrosterone, Placebo; Dietary Supplement · Other
Lead sponsor: Center for Human Reproduction; Other
Eligibility: 21 Years to 37 Years · Female only
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Turner Syndrome, Ovarian Failure, Premature, Sex Chromosome Aberrations, Menopause, Perimenopause
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Primary Ovarian Insufficiency, Low Ovarian Reserve, Premature Ovarian Failure
Interventions: ROSE-1 Protocol; Procedure
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years and older · Female only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Menopausal Syndrome
Interventions: Estradiol (E2), Progesterone (P10) x90, Progesterone (P10) x10; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 45 Years to 55 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Premature Ovarian Failure
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: 20 Years to 40 Years · Female only
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Autoimmune Disease, Infertility, Premature Ovarian Failure
Interventions: Not listed
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 18 Years to 39 Years · Female only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1992 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy, Osteoporosis, Premature Ovarian Failure
Interventions: TMTDS; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 18 Years to 32 Years · Female only
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Ovarian Failure, Infertility, Female
Interventions: intra-ovarian platelet rich plasma injection; Other
Lead sponsor: Reproductive Medicine Associates of New Jersey; Other
Eligibility: 18 Years to 38 Years · Female only
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Basking Ridge, New Jersey

Conditions: Dysfunction; Endocrine, Effects of Chemotherapy, Premature Ovarian Failure
Interventions: Not listed
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Premature Ovarian Failure
Interventions: Estradiol/Medroxyprogesterone acetate; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 18 Years to 40 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Early Menopause, Menopause
Interventions: Nitrate supplementation, placebo; Dietary Supplement
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 60 Years to 70 Years · Female only
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Perimenopausal Disorder, Menopause, Menopause, Premature, Menopause Related Conditions, Menopause Premature Symptomatic, Menopause Premature Asymptomatic, Premature Ovarian Failure, Premature Ovarian Failure, Familial, Premature Ovarian Failure 2A, Premature Ovarian Failure 3, Premature Ovarian Failure 4, Premature Ovarian Failure 1, Premature Ovarian Failure 5, Premature Ovarian Failure 6, Premature Ovarian Failure 7, Premature Ovarian Failure 9, Premature Ovarian Failure 8, Infertility, Infertility, Female, Infertility Unexplained
Interventions: Autologous PRP injection into human ovarian tissue; Other
Lead sponsor: Ascendance Biomedical; Industry
Eligibility: 35 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Carlsbad, California

Conditions: Hypertension, Menopause, Premature, Menopause, Blood Pressure
Interventions: Microneurography to measure muscle sympathetic nerve activity (MSNA), Baroreflex sensitivity testing, Sympathoexcitatory Maneuvers, Blood tests; Diagnostic Test
Lead sponsor: University of Minnesota; Other
Eligibility: 35 Years to 70 Years · Female only
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Turner Syndrome, Primary Ovarian Insufficiency (Poi)
Interventions: Micronized progesterone 200 MG, Micronized Progesterone 100 MG; Drug
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 12 Years to 20 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Primary Ovarian Insufficiency, Female Infertility Due to Diminished Ovarian Reserve
Interventions: Testosterone cream (0.5mg per gram), DHEA, Placebo; Drug · Dietary Supplement
Lead sponsor: Center for Human Reproduction; Other
Eligibility: 38 Years to 44 Years · Female only
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2022
U.S. locations: 2
States / cities: New York, New York • Rochester, New York

Conditions: Cancer, Risk of Premature Ovarian Failure, Fertility Preservation
Interventions: surgery to remove ovaries or high dose chemotherapy; Procedure
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: Up to 45 Years · Female only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Turner Syndrome, Hypogonadism, Premature Ovarian Failure
Interventions: 17 beta estradiol; Drug
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 10 Years to 16 Years · Female only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Premature Ovarian Insufficiency
Interventions: Progesterone, Estrogen Patch; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 11 Years to 19 Years · Female only
Enrollment: 185 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Amenorrhea, Hypoaldosteronism, Hypogonadism, Infertility, Premature Ovarian Failure
Interventions: Not listed
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 18 Years to 42 Years · Female only
Enrollment: 1,134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1991 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Premature Ovarian Insufficiency, Diminished Ovarian Reserve
Interventions: VL-PX10; Drug
Lead sponsor: Vitti Labs, LLC; Industry
Eligibility: 18 Years to 43 Years · Female only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Female Infertility Due to Diminished Ovarian Reserve
Interventions: Human Growth Hormone, Follicle Stimulating Hormone; Drug
Lead sponsor: Center for Human Reproduction; Other
Eligibility: 18 Years to 44 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Primary Ovarian Insufficiency, Infertility
Interventions: In Vitro Follicle Activation (IVA), Follicle Activation; Procedure · Drug
Lead sponsor: National Foundation for Fertility Research; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 2
States / cities: Lone Tree, Colorado

Conditions: Menopausal Complaints, Vaginal Atrophy, Genitourinary Symptoms, HIV (Human Immunodeficiency Virus), Menopause Related Conditions, Vaginitis, Perimenopause
Interventions: Vaginal estradiol tablets, Vaginal moisturizer; Drug · Other
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 40 Years to 70 Years · Female only
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: The Bronx, New York

Search by objective public record fields.

Impact of Treatment Induced Premature Menopause on Quality of Life

Study of Oral Dehydroepiandrosterone(DHEA) to Treat Previously Unexplained Infertility

Dry Eye in Women With Turner Syndrome and Women With Premature Ovarian Failure

Rejuvenation of Premature Ovarian Failure With Stem Cells

Early Menopause Hormone Treatment and Cognition

X-Chromosome Inactivation Status and Premature Ovarian Failure

Steroid Therapy in Autoimmune Premature Ovarian Failure

Hormone Replacement in Young Women With Premature Ovarian Failure

Ovarian Rejuvenation for Premature Ovarian Insufficiency and Poor Ovarian Response

Blood Spot Self-administered Test and Assay

Effects of an Estrogen Replacement Therapy Skin Patch on Ovulation in Women With Premature Ovarian Failure

Influence of Early Menopause on Sympathetic Activation and Cardiovascular Function in Older Women

Inovium Ovarian Rejuvenation Trials

Autonomic Regulation of Blood Pressure in Premature and Early Menopausal Women

Bleeding Patterns in Sequential and Continuous Progesterone Supplementation in Adolescents With Turner Syndrome

Effect of Testosterone Treatment on Embryo Quality

Cryopreservation of Ovarian Tissue

Estrogen Treatment (Oral vs. Patches) in Turner Syndrome

Hormone Replacement Therapy in Adolescents With Premature Ovarian Insufficiency

Ovarian Follicle Function in Patients With Primary Ovarian Failure

A Proof of Concept Study to Evaluate Exosomes From Human Mesenchymal Stem Cells in Women With Premature Ovarian Insufficiency (POI)

Human Growth Hormone Pre-treatment for 6 Weeks Prior to Ovulation Induction for IVF

In Vitro Follicle Activation

Vaginal Estradiol vs Moisturizer to Improve Postmenopausal Vaginal Aging Symptoms and the Microbiome in Women Living With HIV